Oxford Biomedica
Directorship notification under UK Listing Rule 6.4.9
(2)
Oxford, UK - 9 August 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or
"the Company"), a quality and innovation-led cell and gene therapy
CDMO, today announces that Heather Preston, Non-Executive
Director, has been appointed as Non-Executive Director of Aligos
Therapeutics, a Nasdaq listed company, effective 7 August
2024.
-Ends-
|
For further
information, please contact:
|
|
|
Oxford
Biomedica plc:
Natalie Walter, Company Secretary
|
Tel: +44 (0)1865 783 000
|
About Oxford
Biomedica
Oxford Biomedica (LSE: OXB) is a
quality and innovation-led contract development and manufacturing
organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients
around the world.
One of the original pioneers in cell
and gene therapy, OXB has more than 25 years of experience in viral
vectors; the driving force behind the majority of cell and gene
therapies. OXB collaborates with some of the world's most
innovative pharmaceutical and biotechnology companies, providing
viral vector development and manufacturing expertise in lentivirus,
adeno-associated virus (AAV), adenovirus, and other viral vector
types. Oxford Biomedica's world-class capabilities span from
early-stage development to commercialisation. These
capabilities are supported by robust quality-assurance systems,
analytical methods and depth of regulatory expertise.
OXB offers a vast number of unique technologies
for viral vector manufacturing, including a 4th generation
lentiviral vector system (the TetravectaTM system), dual
plasmid system for AAV production, suspension and perfusion process
using process enhancers and stable producer and packaging cell
lines.
Oxford Biomedica, a FTSE4Good
constituent, is headquartered in Oxford, UK. It has
bioprocessing and manufacturing facilities across Oxfordshire, UK,
Lyon and Strasbourg, France, and near Boston, MA, US. Learn more
at www.oxb.com, and follow us
on LinkedIn and YouTube.